Crossmark

SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients

Crossref DOI link: https://doi.org/10.1186/s12885-018-4298-5

Published Online: 2018-04-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mei, Zhu

Shao, Yang W.

Lin, Peinan

Cai, Xiaomin

Wang, Biao

Ding, Yan

Ma, Xiangyuan

Wu, Xue

Xia, Yewei

Zhu, Dongqin

Shu, Yongqian

Fu, Zan

Gu, Yanhong
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (91429308, 81572389)

Science and Technology Development Foundation of Nanjing Medical University (2016NJMU064)
License Information

Text and Data Mining valid from 2018-04-27
More Information

Article History

Received: 10 October 2017

Accepted: 22 March 2018

First Online: 27 April 2018

Ethics approval and consent to participate

: This study was approved by the ethic committee of the First Affiliated Hospital with Nanjing Medical University. All the patients enrolled in this study have provided written informed consents for specimen collection, genetic testing, and participation in the research anonymously.

: Not applicable.

: Yang W. Shao, Yan Ding, Xiangyuan Ma, and Xue Wu are the shareholders or employees of Geneseeq Technology Inc.; Yewei Xia, and Dongqin Zhu are the employee of Nanjing Geneseeq Technology Inc..

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.